Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
- PMID: 21765042
- DOI: 10.1093/annonc/mdr316
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
Abstract
Background: Several lines of evidence suggest that cytokines released as a result of wound healing might reactivate dormant breast cancer metastases. To test this, we examined if accidental trauma or surgery, unrelated to the original cancer, might stimulate the growth of dormant micrometastases and be related to an increase in the recurrence rate in the period after the event.
Methods: To test this hypothesis, we used data from the ATAC [Arimidex (anastrozole), tamoxifen alone or in combination] trial and coded the data for women who have experienced trauma or surgical procedures unrelated to the cancer. For the initial analysis, we considered recurrences occurring 2-24 months after the traumatic event and also between 2 and 12 months after trauma. In a secondary analysis, we also looked at recurrences in the first 2 months after event.
Results: The hazard ratio (HR) for recurrence 2-24 months after event was 0.96 [confidence interval (CI) 0.86-1.07, P = 0.48]; for 2-12 months, it was 0.96 (CI 0.82-1.11, P = 0.58) and for 0-2 months, the HR was 0.87 (CI 0.54-1.38 P = 0.87).
Conclusion: Trauma was not associated with an increased rate of breast cancer recurrence in the 24-month window after the event in this large study.
Similar articles
-
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.Cancer. 2003 Nov 1;98(9):1802-10. doi: 10.1002/cncr.11745. Cancer. 2003. PMID: 14584060 Clinical Trial.
-
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.Support Care Cancer. 2006 Sep;14(9):917-27. doi: 10.1007/s00520-006-0035-8. Epub 2006 Apr 5. Support Care Cancer. 2006. PMID: 16596419
-
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):399-403. doi: 10.1016/s0960-0760(03)00350-9. J Steroid Biochem Mol Biol. 2003. PMID: 14623537 Clinical Trial.
-
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).Recent Results Cancer Res. 2003;163:96-103; discussion 264-6. doi: 10.1007/978-3-642-55647-0_9. Recent Results Cancer Res. 2003. PMID: 12903846 Review.
-
Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.Breast Cancer Res Treat. 2003;80 Suppl 1:S3-11; discussion S13-8. doi: 10.1023/a:1025455130476. Breast Cancer Res Treat. 2003. PMID: 14535530 Review.
Cited by
-
Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction.Br J Surg. 2018 Oct;105(11):1435-1445. doi: 10.1002/bjs.10866. Epub 2018 Apr 23. Br J Surg. 2018. PMID: 29683203 Free PMC article.
-
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse.Semin Cancer Biol. 2022 Jan;78:17-22. doi: 10.1016/j.semcancer.2021.03.023. Epub 2021 Mar 27. Semin Cancer Biol. 2022. PMID: 33785450 Free PMC article. Review.
-
Stimuli-induced organ-specific injury enhancement of organotropic metastasis in a spatiotemporal regulation.Pathol Oncol Res. 2014 Jan;20(1):27-42. doi: 10.1007/s12253-013-9734-x. Epub 2013 Dec 20. Pathol Oncol Res. 2014. PMID: 24357158 Review.
-
Awakening of Dormant Breast Cancer Cells in the Bone Marrow.Cancers (Basel). 2023 Jun 1;15(11):3021. doi: 10.3390/cancers15113021. Cancers (Basel). 2023. PMID: 37296983 Free PMC article. Review.
-
Distant metastasis dynamics following subsequent surgeries after primary breast cancer removal.Breast Cancer Res. 2019 May 2;21(1):57. doi: 10.1186/s13058-019-1139-7. Breast Cancer Res. 2019. PMID: 31046808 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical